A Phase I, Open Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies

Trial Profile

A Phase I, Open Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Colorectal cancer; Connective and soft tissue neoplasms; Gastric cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Skin cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 07 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 26 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top